Company intelligence / Profile preview

MedicQuant

Ownership: Private
Development stage: Preclinical

Overview

MedicQuant has developed a rapid, point-of-care diagnostic device capable of detecting anticoagulant drugs directly from whole blood samples within 10 minutes. The technology requires no sample preparation and is designed for use in emergency settings to support faster treatment decisions. The company spun out from Aarhus University and leverages technology developed by its founders.

Therapeutic areas: CardiovascularHematology
Modalities: Device (Point-of-care diagnostic device)
Industry: Physiological Monitoring

Beyond the preview

Go deeper on MedicQuant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedicQuant.

Explore the full profile